Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Apr 5, 2022
Politics, Policy & Law
April 4 Quick Takes: University of California continues CRISPR IP fight
Plus Protalix gains on Fabry data and updates from Alnylam, Curis, Gilead, BMS
BioCentury | Oct 7, 2021
Product Development
Fabry disease’s five-year prospects look up
Comparing the profiles of up-and-coming therapies for Fabry disease
BioCentury | Jun 13, 2019
Product Development
Why BioMarin took gene therapy manufacturing into its own hands
The factors behind BioMarin’s decision to build rather than buy a facility for manufacturing gene therapies.
BioCentury | Sep 1, 2018
Politics, Policy & Law
Back to School 2018: A pathway to Biopharma 3.0
Back to School 2018: How external disrupters will drive biopharma to new business model
BioCentury | May 20, 2017
Strategy
Henri: N of 1
How the late Genzyme CEO Henri Termeer created the Orphan drug industry
BioCentury | Mar 28, 2016
Strategy
Canbridge can-can
Why Aveo's AV-203 is leading Canbridge to venture outside Asia
Items per page:
1 - 10 of 288